ROIV Roivant Sciences PE ratio, current and historical analysis
The current PE ratio of ROIV can't be determined, as the TTM EPS of -$0.19 is negative. The last PE ratio of Roivant Sciences, recorded in September 2024, was 1.94.
ROIV PE ratio history
How has ROIV's PE ratio performed in the past
Today
N/A
Average
N/A
Median
N/A
Minimum
N/A
Maximum
N/A
Roivant Sciences PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 1.9 | N/A | $10.54 | $5.55 |
| 2023 | N/A | N/A | $7.38 | -$1.42 |
| 2022 | N/A | N/A | $4.94 | -$1.26 |
| 2021 | N/A | N/A | $9.78 | -$1.28 |
| 2020 | N/A | N/A | N/A | $5.13 |
Roivant Sciences PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | N/A | N/A | $11.83 | -$0.19 |
| Sep 2024 | 1.94 | 7.78% | $11.54 | $5.95 |
| Jun 2024 | 1.8 | -5.26% | $10.57 | $5.86 |
| Mar 2024 | 1.9 | -5.94% | $10.54 | $5.55 |
| Dec 2023 | 2.02 | N/A | $11.23 | $5.56 |
| Sep 2023 | N/A | N/A | $11.68 | -$1.3 |
| Jun 2023 | N/A | N/A | $10.08 | -$1.32 |
| Mar 2023 | N/A | N/A | $7.38 | -$1.42 |
| Dec 2022 | N/A | N/A | $7.99 | -$1.78 |
| Sep 2022 | N/A | N/A | $3.22 | -$1.7 |
| Jun 2022 | N/A | N/A | $4.07 | -$1.6 |
| Mar 2022 | N/A | N/A | $4.94 | -$1.26 |
| Dec 2021 | N/A | N/A | $10.08 | -$1.66 |
| Sep 2021 | N/A | N/A | $9.35 | -$1.66 |
| Jun 2021 | N/A | N/A | $9.89 | -$1.4 |
ROIV average PE ratio chart
What is the average PE ratio of ROIV for the past years
3-year avg
N/A
5-year avg
N/A
10-year avg
N/A
15-year avg
N/A
ROIV PE vs peers
What is ROIV's PE ratio compared to its peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| OLMA Olema Pharmaceuticals Inc | N/A | $230.28M |
| OMER Omeros Corp | N/A | $432M |
| ONVO Organovo Holdings Inc | N/A | $3.16M |
| ORIC Oric Pharmaceuticals Inc | N/A | $370.76M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $89.46M |
| ROIV Roivant Sciences Ltd | N/A | $7.15B |
Frequently asked questions
What is Roivant Sciences's PE ratio?
The current price to earnings ratio of ROIV can't be calculated, as its EPS of -$0.19 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.